Sigrid Therapeutics is a clinical-stage biotechnology company pioneering a new class of therapies to prevent and treat lifestyle diseases. SiPore15™ is Sigrid Therapeutics’ lead product candidate in clinical development, originating from research at Stockholm University and Karolinska Institute. SiPore15™ is a breakthrough particle for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics.
Sigrid Therapeutics
Transforming the way Sigrid Therapeutics prevents and treat chronic lifestyle diseases.
